Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 43

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---

impact of the adoption of this standard on the related disclosures.

In
December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures. This ASU does not change accounting for income
taxes but requires new disclosures focusing on two areas, the effective rate reconciliation and taxes paid. This new standard is effective
for public business entities for annual periods beginning after December 15, 2024. Early adoption is permitted. 

NOTE
3: PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid
expenses and other current assets were comprised of the following:

SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS 

    June 30, 2025  
    December 31, 2024 
  
    Prepaid insurance 
    $83,698  
    $506,489 
  
    Prepaid research and development 
     2,700  
     150,000 
  
    Other prepaid expenses 
     168,959  
     175,088 
  
    Total prepaid expenses and other current assets 
    $255,357  
    $831,577 
  
    Prepaid
    expenses and other current assets 
    $255,357  
    $831,577 

NOTE
4: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts
payable and other current liabilities were comprised of the following:

SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES 

    June 30, 2025  
    December 31, 2024 
  
    Accounts payable 
    $618,515  
    $870,229 
  
    Accrued employee costs 
     85,887  
     1,371,498 
  
    Accrued professional fees 
     83,680  
     72,054 
  
    Accrued research and development 
     1,103,446  
     860,958 
  
    Accrued board fees 
     58,876  
     117,750 
  
    Other accrued expenses 
     25,283  
     17,228 
  
    Total accounts payable and other current liabilities 
    $1,975,687  
    $3,309,717 

NOTE
5: STOCK-BASED COMPENSATION

The
Company has an equity incentive plan for grants